Statement re Share Price Movement

Summary by AI ^BETAClose X

ProBiotix Health plc notes a recent fall in its share price and states there are no fundamental commercial or operational reasons for this movement, believing it may stem from mistaken assumptions regarding events at SkinBioTherapeutics plc. While both companies were originally formed by OptiBiotix Health plc, which remains a significant shareholder in both, ProBiotix confirms there are no other commercial or operational links and that recent events at SkinBioTherapeutics have no bearing on its business. The company reiterates that trading momentum remains strong as previously reported and anticipates updating shareholders on its progress.

Disclaimer*

Probiotix Health PLC

16 February 2026

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

Statement regarding Share Price Movement

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, notes the recent fall in the Company's share price.

The Directors of the Company know of no fundamental commercial or operational reasons for this movement, which the Directors believe may result from mistaken assumptions about recent events at SkinBioTherapeutics plc (SBTX).

ProBiotix and SBTX were originally both formed by OptiBiotix Health plc (OPTI), and OPTI remains a significant shareholder in both companies.

Beyond that, there are no commercial or operational links between ProBiotix and SBTX, and recent events at SBTX have no bearing whatsoever on the business of the Company.

Further to the update issued by ProBiotix on 21 January 2026, the Board is pleased to confirm that trading momentum remains as strong as previously reported, and we look forward to updating our shareholders on our progress.

For further information, please contact:

ProBiotix Health plc	https://probiotixhealth-ir.com/
	investors@probiotixhealth.com
Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations

AlbR Capital Limited Aquis Corporate Adviser and Broker	Tel: 020 7469 0930

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Notes to Editors:

ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

The Company has a singular approach: discovering groundbreaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END